Hemenway Trust Co LLC Raises Holdings in Danaher Co. (NYSE:DHR)

Hemenway Trust Co LLC boosted its holdings in Danaher Co. (NYSE:DHR) by 0.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 156,379 shares of the conglomerate’s stock after acquiring an additional 1,438 shares during the period. Danaher comprises about 3.4% of Hemenway Trust Co LLC’s investment portfolio, making the stock its 8th biggest holding. Hemenway Trust Co LLC’s holdings in Danaher were worth $43,477,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Savvy Advisors Inc. increased its stake in shares of Danaher by 402.8% in the third quarter. Savvy Advisors Inc. now owns 4,349 shares of the conglomerate’s stock valued at $1,209,000 after purchasing an additional 3,484 shares during the period. Ashton Thomas Private Wealth LLC increased its stake in shares of Danaher by 1.3% in the third quarter. Ashton Thomas Private Wealth LLC now owns 5,365 shares of the conglomerate’s stock valued at $1,492,000 after purchasing an additional 68 shares during the period. Verus Capital Partners LLC acquired a new stake in shares of Danaher in the third quarter valued at approximately $203,000. WealthPlan Investment Management LLC increased its stake in shares of Danaher by 28.4% during the third quarter. WealthPlan Investment Management LLC now owns 26,436 shares of the conglomerate’s stock valued at $7,350,000 after acquiring an additional 5,842 shares during the period. Finally, Harbour Investments Inc. increased its stake in shares of Danaher by 3.0% during the third quarter. Harbour Investments Inc. now owns 1,531 shares of the conglomerate’s stock valued at $426,000 after acquiring an additional 45 shares during the period. Institutional investors own 79.05% of the company’s stock.

Insider Activity at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Performance

DHR stock traded up $0.22 during mid-day trading on Tuesday, reaching $243.47. 184,724 shares of the stock traded hands, compared to its average volume of 2,735,135. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. Danaher Co. has a 52 week low of $193.75 and a 52 week high of $281.70. The business has a 50-day moving average of $264.37 and a two-hundred day moving average of $260.82. The firm has a market capitalization of $175.85 billion, a PE ratio of 46.42, a P/E/G ratio of 4.51 and a beta of 0.85.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter last year, the company earned $2.02 earnings per share. The firm’s revenue was up 3.1% on a year-over-year basis. As a group, equities analysts predict that Danaher Co. will post 7.51 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is presently 20.61%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of research analyst reports. Raymond James lowered their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Robert W. Baird lowered their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. KeyCorp raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group decreased their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Finally, Stifel Nicolaus lifted their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.